Last updated on November 2017

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients with Atopic Dermatitis


Brief description of study

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients with Atopic Dermatitis

Detailed Study Description

A Phase 3 Study Investigating the Efficacy And Safety of Multiple Dupilumab Dose Gimens Administered as Monotherapy for Maintaining Treatment Response in Patients with Atopic Dermatitis

Clinical Study Identifier: TX81852

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Columbus Regional Research Institute

Columbus Regional Research Institute
Columbus, GA USA
  Connect »